Brevan Howard Capital Management LP Verve Therapeutics, Inc. Transaction History

Brevan Howard Capital Management LP

  • $13.9 Billion
  • Q4 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$4.76 - $12.79 $113,202 - $304,171
23,782 New
23,782 $116,000
Q4 2023

Feb 14, 2024
BUY
$8.84 - $18.7 $130,310 - $275,656
14,741 New
14,741 $205,000

Others Institutions Holding VERV

# of Institutions
180
Shares Held
76.4M
Call Options Held
70.3K
Put Options Held
194K
View Full List

About Verve Therapeutics, Inc.

VERV Quotes by TradingView
  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $396M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Brevan Howard Capital Management LP Portfolio

Follow Brevan Howard Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brevan Howard Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Brevan Howard Capital Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email